GlobeNewsWire · IMMP · November 18, 2026
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗